Related references
Note: Only part of the references are listed.A White Paper-Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements
J. M. Sailstad et al.
AAPS JOURNAL (2014)
New FDA Draft Guidance on Immunogenicity
Ashwin Parenky et al.
AAPS JOURNAL (2014)
Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study
Heather Myler et al.
BIOANALYSIS (2014)
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3-LBA and immunogenicity)
Lauren Stevenson et al.
BIOANALYSIS (2014)
The Immunogenicity of Polyethylene Glycol: Facts and Fiction
Huub Schellekens et al.
PHARMACEUTICAL RESEARCH (2013)
Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
Ricardo P. Garay et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers
Yijuan Liu et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2011)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients
Jonathan K. Armstrong et al.
CANCER (2007)
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes
Sean E. Doyle et al.
HEPATOLOGY (2006)
Lambda interferon inhibits hepatitis B and C virus replication
MD Robek et al.
JOURNAL OF VIROLOGY (2005)
IL-28, IL-29 and their class II cytokine receptor IL-28R
P Sheppard et al.
NATURE IMMUNOLOGY (2003)
IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex
SV Kotenko et al.
NATURE IMMUNOLOGY (2003)
Share Paper
